Kris Wood

Kris Wood

Duke University

H-index: 27

North America-United States

About Kris Wood

Kris Wood, With an exceptional h-index of 27 and a recent h-index of 24 (since 2020), a distinguished researcher at Duke University, specializes in the field of cancer, genomics, targeted therapies, cell signaling.

His recent articles reflect a diverse array of research interests and contributions to the field:

A novel dual ATM/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors

Drug dependence in cancer is exploitable by optimally constructed treatment holidays

Executioner caspases restrict mitochondrial RNA-driven Type I IFN induction during chemotherapy-induced apoptosis

CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer

Endogenous and imposed determinants of apoptotic vulnerabilities in cancer

Hyperactivation of oncogenic driver pathways as a precision therapeutic strategy

MCB-613 exploits a collateral sensitivity in drug resistant EGFR-mutant non-small cell lung cancer through covalent inhibition of KEAP1

Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13

Kris Wood Information

University

Position

___

Citations(all)

4018

Citations(since 2020)

2236

Cited By

2646

hIndex(all)

27

hIndex(since 2020)

24

i10Index(all)

42

i10Index(since 2020)

39

Email

University Profile Page

Duke University

Google Scholar

View Google Scholar Profile

Kris Wood Skills & Research Interests

cancer

genomics

targeted therapies

cell signaling

Top articles of Kris Wood

Title

Journal

Author(s)

Publication Date

A novel dual ATM/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors

Molecular Cancer Therapeutics

Tona M Gilmer

Chun-Hsiang Lai

Kexiao Guo

Katherine Deland

Kathleen A Ashcraft

...

2024/4/8

Drug dependence in cancer is exploitable by optimally constructed treatment holidays

Nature Ecology & Evolution

Jeff Maltas

Shane T Killarney

Katherine R Singleton

Maximilian AR Strobl

Rachel Washart

...

2024/1

Executioner caspases restrict mitochondrial RNA-driven Type I IFN induction during chemotherapy-induced apoptosis

Nature Communications

Shane T Killarney

Rachel Washart

Ryan S Soderquist

Jacob P Hoj

Jamie Lebhar

...

2023/3/14

CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer

Molecular Cancer Research

Lyla J Stanland

Hazel X Ang

Jacob P Hoj

Yunqiang Chu

Patrick Tan

...

2023/11/1

Endogenous and imposed determinants of apoptotic vulnerabilities in cancer

Kristopher A Sarosiek

Kris C Wood

2023/2/1

Hyperactivation of oncogenic driver pathways as a precision therapeutic strategy

Nature Genetics

Kris C Wood

2023/10

MCB-613 exploits a collateral sensitivity in drug resistant EGFR-mutant non-small cell lung cancer through covalent inhibition of KEAP1

bioRxiv

Christopher F Bassil

Gray R Anderson

Benjamin Mayro

Kayleigh N Askin

Peter S Winter

...

2023/1/19

Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13

Proceedings of the National Academy of Sciences

Hazel X Ang

Natalia Sutiman

Xinyue L Deng

Annie Liu

Christian G Cerda-Smith

...

2023/9/19

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer

Cancer research

Craig M Goodwin

Andrew M Waters

Jennifer E Klomp

Sehrish Javaid

Kirsten L Bryant

...

2023/1/4

Sublethal engagement of apoptotic pathways in residual cancer

Shane T Killarney

Stephen WG Tait

Douglas R Green

Kris C Wood

2023/8/10

ABL kinases regulate the stabilization of HIF-1α and MYC through CPSF1

Proceedings of the National Academy of Sciences

Benjamin Mayro

Jacob P Hoj

Christian G Cerda-Smith

Haley M Hutchinson

Michael W Caminear

...

2023/4/18

Concurrent inhibition of ERK and farnesyltransferase suppresses the growth of HRAS mutant head and neck squamous cell carcinoma

Molecular cancer therapeutics

Sehrish Javaid

Antje Schaefer

Craig M Goodwin

Victoria V Nguyen

Frances L Massey

...

2022/5/4

Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies

NPJ Precision Oncology

Michael E Lidsky

Zechen Wang

Min Lu

Annie Liu

S David Hsu

...

2022/10/23

Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells

Science translational medicine

Moiez Ali

Min Lu

Hazel Xiaohui Ang

Ryan S Soderquist

Christine E Eyler

...

2022/3/30

Cancer genes disfavoring T cell immunity identified via integrated systems approach

Cell reports

Rigel J Kishton

Shashank J Patel

Amy E Decker

Suman K Vodnala

Maggie Cam

...

2022/8/2

A high throughput proliferation and cytotoxicity assay for co-cultured isogenic cell lines

MethodsX

Syed Ahmad

Kris C Wood

John E Scott

2022/1/1

P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia

Nature cancer

Kevin H Lin

Justine C Rutter

Abigail Xie

Shane T Killarney

Camille Vaganay

...

2022/7

Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant …

Molecular cancer therapeutics

Natalia Garcia

Vanessa Del Pozo

Marielle E Yohe

Craig M Goodwin

Terry J Shackleford

...

2022/1/1

A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models

The Journal of Clinical Investigation

Zheng Zhong

Nathan Harmston

Kris C Wood

Babita Madan

David M Virshup

2022/6/15

Drivers of intrinsic resistance

Nature chemical biology

Kris C Wood

2022/6

See List of Professors in Kris Wood University(Duke University)